St. Jude Children's Research Hospital

The U.S. FDA has approved Merck's ENFLONSIA (clesrovimab-cfor), a long-acting monoclonal antibody for preventing RSV lower respiratory tract disease in newborns and infants entering their first RSV season.

Children with sickle cell disease taking hydroxyurea experienced fewer emergency room visits and shorter hospital stays compared to those not on the therapy, according to a study of 2,147 pediatric patients.

A child in Alameda County, California has tested positive for H5N1 bird flu despite having no known contact with infected animals, raising concerns about potential transmission pathways.

A Louisiana patient hospitalized with H5N1 avian influenza marks the first severe human case in the United States, with genetic analysis revealing mutations that could enhance the virus's ability to infect human cells.

• St. Jude Children's Research Hospital's HIV clinical research program explores innovative long-acting treatments, including a groundbreaking six-month regimen combining antibodies and capsid inhibitors. • A significant breakthrough led to FDA approval of injectable antiretrovirals (cabotegravir and rilpivirine) for youth aged 12 and older, offering an alternative to daily oral medications. • Through narrative medicine approach, trial participants share personal experiences, highlighting the human impact of HIV treatment advances while maintaining anonymity due to stigma.

Dr. Ching Pui's groundbreaking research at St. Jude Children's Research Hospital has dramatically improved pediatric ALL survival rates from 40% to 94% through innovative treatment protocols and minimal residual disease-directed therapy.

Doctors at Children's Hospital of Philadelphia successfully treated a baby with CPS1 deficiency using a custom-designed CRISPR base editing therapy, marking a groundbreaking advancement in personalized genetic medicine.

St. Jude Children's Research Hospital trials show genomics and early treatment response can guide risk classification in B-cell acute lymphoblastic leukemia (B-ALL).

A groundbreaking gene therapy developed by US scientists has effectively cured infants with X-linked severe combined immunodeficiency (X-SCID), a rare and fatal genetic disorder that leaves children without functioning immune systems.